Chen Da-Chung, Chung Yueh-Fang, Yeh Yao-Tsug, Chaung Hso-Chi, Kuo Fu-Chen, Fu Ou-Yang, Chen Hue-Yong, Hou Ming-Feng, Yuan Shyng-Shou F
Department of Medical Research and Department of Obstetrics and Gynecology, E-Da Hospital, I-Shou University, Kaohsiung County, Taiwan, R.O.C.
Cancer Lett. 2006 Jun 8;237(1):109-14. doi: 10.1016/j.canlet.2005.05.047. Epub 2005 Jul 12.
The role of two adipocytokines, adiponectin and leptin, in Taiwanese breast cancer patients remains to be determined. In this study, we analyzed the correlations between the serum levels of adiponectin and leptin and the various clinicopathological parameters in 100 newly diagnosed, histologically confirmed breast cancer patients and 100 controls. We found serum levels were decreased significantly for adiponectin in the breast cancer patients, in comparison to controls (Student t-test, P=0.003), while serum levels were increased significantly for leptin in the breast cancer patients in comparison to controls (Student t-test, P=0.025). Leptin/adiponectin (L/A ratio) were increased significantly in the breast cancer patients, in comparison to controls (Student t-test, P=0.009). Among the clinicopathological parameters, estrogen receptor, progesterone receptor, HER2/neu, lymph node metastasis, tumor stage, and tumor grade all showed no effect on the serum levels of adiponectin and leptin. BMI was negatively and positively correlated to serum adiponectin and leptin levels, respectively (Spearman's correlation, r=-0.333 and 0.323, respectively; P<0.001 for both). Intriguingly, serum L/A ratio disclosed a positive correlation to tumor size (r=0.21, P=0.036). In summary, our results suggest that low serum adiponectin levels and high serum leptin levels are associated with an increased risk for breast cancer. Also, independent of the effect of BMI, the increased serum ratio of L/A may indicate the presence of aggressive breast cancers.
脂联素和瘦素这两种脂肪细胞因子在台湾乳腺癌患者中的作用尚待确定。在本研究中，我们分析了100例新诊断的、经组织学确诊的乳腺癌患者和100例对照者血清中脂联素和瘦素水平与各种临床病理参数之间的相关性。我们发现，与对照组相比，乳腺癌患者血清脂联素水平显著降低（学生t检验，P = 0.003），而与对照组相比，乳腺癌患者血清瘦素水平显著升高（学生t检验，P = 0.025）。与对照组相比，乳腺癌患者的瘦素/脂联素（L/A比值）显著升高（学生t检验，P = 0.009）。在临床病理参数中，雌激素受体、孕激素受体、HER2/neu、淋巴结转移、肿瘤分期和肿瘤分级对脂联素和瘦素的血清水平均无影响。BMI分别与血清脂联素和瘦素水平呈负相关和正相关（Spearman相关性分析，r分别为-0.333和0.323；两者P均<0.001）。有趣的是，血清L/A比值与肿瘤大小呈正相关（r = 0.21，P = 0.036）。总之，我们的结果表明，血清脂联素水平低和血清瘦素水平高与乳腺癌风险增加有关。此外，独立于BMI的影响，血清L/A比值升高可能表明存在侵袭性乳腺癌。
